Related Experiment Video
Updated: May 28, 2026
10:21
Proliferation and Differentiation of Murine Myeloid Precursor 32D/G-CSF-R Cells
Published on: February 21, 2018
Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts.
E Papaemmanuil1, M Cazzola, J Boultwood
1Cancer Genome Project, Wellcome Trust Sanger Institute, Hinxton, United Kingdom
The New England Journal of Medicine
|October 15, 2011
Summary
Mutations in the SF3B1 gene are common in myelodysplastic syndromes, particularly those with ring sideroblasts. These SF3B1 mutations impact RNA splicing and are linked to better clinical outcomes.
Area of Science:
- Genetics
- Oncology
- Molecular Biology
Background:
- Myelodysplastic syndromes (MDS) are common chronic hematologic cancers.
- Identifying novel genetic alterations is crucial for advancing MDS diagnostics and therapeutics.
Purpose of the Study:
- To identify novel genetic mutations in low-grade myelodysplastic syndromes.
- To investigate the role of SF3B1 mutations in MDS pathogenesis and clinical outcomes.
Main Methods:
- Whole-genome sequencing of protein-coding exons in 9 MDS patients.
- Targeted resequencing of SF3B1 in 2087 patients with myeloid or other cancers.
Main Results:
- Identified recurrent somatic mutations in SF3B1.
- SF3B1 mutations found in 20% of MDS patients, especially those with ring sideroblasts (65%).
- SF3B1 mutations associated with altered gene networks, retained protein function, fewer cytopenias, and longer event-free survival.
Conclusions:
- SF3B1 mutations highlight the role of aberrant mRNA splicing in MDS development.
- SF3B1 mutations may serve as a prognostic biomarker in myelodysplastic syndromes.
